指南与共识生殖医学

ESHRE更新IVF实验室良好实践推荐

ESHRE recommendations on Good Practice in the IVF laboratory†.
指南 / 共识 · Hum Reprod · 2026-01-01

ESHRE工作组基于2015版指南、现有文献证据及专家共识,更新了IVF实验室良好实践推荐,覆盖实验室组织管理及各项操作流程,新增胚胎活检章节。该指南旨在为实验室主任、胚胎学家及技术人员提供实践参考,但部分推荐缺乏证据支持。

要点

  • 更新涵盖IVF实验室组织管理(人员、质量、安全)及具体操作流程的推荐。
  • 胚胎培养与移植章节被拆分,精子准备章节扩展至所有男科操作,新增活检章节。
  • 部分推荐基于专家共识而非证据,需结合临床判断个体化应用。

核心结论

  • ESHRE发布了IVF实验室良好实践的更新推荐,覆盖实验室所有活动。
  • 该指南基于现有文献证据和工作组专家共识制定,部分推荐缺乏证据支持。

研究设计与样本

  • 指南由ESHRE工作组制定,采用预设方法学,工作组共10名成员,代表胚胎学、安全与质量及男科学特别兴趣小组。
  • 工作组回顾2015版文件,各成员更新一个或多个章节,推荐经讨论达成共识,并经利益相关者审查及ESHRE执行委员会批准。

主要发现

  • 更新涉及实验室一般组织(人员配置与指导、质量管理、实验室安全)及具体操作(患者识别与配子追溯、耗材、生物材料处理、取卵、精子准备、授精、受精评分、胚胎培养与移植、胚胎活检、冷冻保存、应急程序)。
  • 胚胎培养与移植章节被拆分,精子准备章节扩展至所有男科操作,新增活检操作章节。

临床怎么用

  • 适用于IVF实验室主任、管理人员、胚胎学家及实验室技术人员的日常管理和操作。
  • 临床应用中需结合个体化临床判断,不能保证特定结局,也不替代当地实际情况的调整。

局限性

  • 并非所有推荐均有证据支持,部分推荐参考了法律文件、相关近期文件、手册及共识文件。
  • 指南不保证成功或特定结局,不建立护理标准,不替代对每个个体表现的临床判断。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: What is the current good practice in the IVF laboratory, based on the best available evidence in the literature, if available, and the expertise of the working group? SUMMARY ANSWER: The updated ESHRE Recommendations on Good Practice in the IVF laboratory provides recommendations on all activities in the IVF laboratory. WHAT IS KNOWN ALREADY?: A previous version of the Good Practice in the IVF laboratory guideline was published in 2015. The adoption of new techniques, the increasing complexity of procedures, and the introduction of a revised European legislation on the quality and safety of tissues and cells for human application pertinent to assisted reproduction together necessitated an update of the document. STUDY DESIGN, SIZE, DURATION: This document was developed according to a predefined methodology for ESHRE Good Practice recommendations. The working group reviewed the document of 2015, and based on this assessment, each group member updated one or more sections. Recommendations are supported by data from the literature, if available, and the expertise of the working group and were discussed until consensus was reached within the working group. PARTICIPANTS/MATERIALS, SETTING, METHODS: The working group included 10 members representing the ESHRE Special Interest Groups for Embryology, Safety and Quality, and Andrology, with different areas of expertise and representing different European countries and settings. Based on the available evidence and the expertise of the working group, recommendations were formulated. Following stakeholder review of the initial draft, the final version was approved by the working group and ultimately by the ESHRE Executive Committee. MAIN RESULTS AND THE ROLE OF CHANCE: The ESHRE IVF labs working group updated the recommendations on the general organization of an IVF laboratory (staffing and direction, quality management, and laboratory safety) and on the specific aspects of the procedures performed in IVF laboratories (identification of patients and traceability of their reproductive cells, consumables, handling of biological material, oocyte retrieval, sperm preparation, insemination of oocytes, scoring for fertilization, embryo culture and transfer, embryo biopsy for pre-implantation genetic testing, cryopreservation, and emergency procedures). The section on embryo culture and transfer was split up, the section on sperm preparation was expanded to cover all general andrological procedures, and a new section on biopsy procedure was introduced. LIMITATIONS, REASONS FOR CAUTION: Not all recommendations are supported by evidence. Other recommendations, published in legal documents, relevant and recent documents, manuals, and consensus papers, were taken into account when formulating the recommendations. WIDER IMPLICATIONS OF THE FINDINGS: The guideline group is confident that this document will be helpful to directors and managers involved in the management and organization of IVF laboratories and also to embryologists and laboratory technicians performing daily tasks. STUDY FUNDING/COMPETING INTEREST(S): The guideline was developed by ESHRE, which funded the guideline meetings, literature searches, and dissemination of the guideline. The guideline group members did not receive any financial incentives; all work was provided voluntarily. G.C. reports consulting fees from Gedeon Richter and Cooper Surgical and was part of the working group of the 'Guide to the quality and safety of tissues and cells for human application' of the European Directorate for the Quality of Medicines and Healthcare, on behalf of the Council of Europe. T.E. reports consulting fees from Nexpring Health and Esco Medical and speaker's fees from Nexpring Health and Esco Medical. J.K.-B. reports research grants from Gates Foundation and NIHR, consulting fees from Bayer, speakers fees from Merck, IBSA, Ferring and Cooper Surgical, and travel support from Merck, IBSA, Ferring, and Cooper Surgical. I.S. reports speaker's fees from Vitrolife and Cooper Surgical. I.S. also declares being a member of ARCS Scientific Committee. The other authors disclosed no conflicts of interest. DISCLAIMER: This guideline represents the views of ESHRE, which were achieved after careful consideration of the scientific evidence available at the time of preparation. In the absence of scientific evidence on certain aspects, a consensus between the relevant ESHRE stakeholders has been obtained. Adherence to these clinical practice guidelines does not guarantee a successful or specific outcome nor does it establish a standard of care. Clinical practice guidelines do not replace the need for application of clinical judgment to each individual presentation nor variations based on locality and facility type. ESHRE makes no warranty, express or implied, regarding the clinical practice guidelines and specifically excludes any warranties of merchantability and fitness for a particular use or purpose (full disclaimer available at www.eshre.eu/guidelines).

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Arroyo G, Barrie A, Coticchio G, et al. ESHRE recommendations on Good Practice in the IVF laboratory†. Hum Reprod. 2026. PMID: 42405499. doi:10.1093/humrep/deag096

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。